Compliance
The EPNS 2019 Congress is compliant with the provisions of the MedTech Europe Code of Ethical Business Practice.
The 3rd EPNS International Advances in Neuromodulation in Children Symposium is compliant with the provisions of the MedTech Europe Code of Ethical Business Practice.
Continuing Medical Education
The 13th European Paediatric Neurology Society (EPNS) Congress, Athens, Greece, 17/09/2019- 21/09/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 24 European CME credits (ECMEC®s). The 3rd EPNS International Advances in Neuromodulation in Children Symposium, Athens, Greece, 16/09/2019-17/09/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 13 European CME credits (ECMEC®s).
EPNS 2019 Congress Industry Sessions
Wednesday, 18 September 2019 Trianti Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 1
From CLN2 diagnosis to treatment: How to keep improving?
Chair: Maria Mazurkiewicz-Bełdzińska (POLAND)
Welcome & Introduction
Maria Mazurkiewicz-Bełdzińska (POLAND)
Lifting the curtain: Key hallmarks of CLN2 disease
Maria Mazurkiewicz-Bełdzińska (POLAND)
Diagnosis to treatment: Hospital/centre readiness
Igor Prpić (CROATIA)
Striving towards treatment excellence
Hidde H. Huidekoper (NETHERLANDS)
Interactive discussion: advancing care together
All
Sponsored by
Wednesday, 18 September 2019 Skalkotas Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 2
Challenges of Developmental Epileptic Encephalopathies: shaping thefuture?
Co-Chairs: Artemis Gika (GREECE), Alexis Arzimanoglou (FRANCE)
13:00-13:10 Welcome & Introduction
Artemis Gika (GREECE)
13:10-13:30 Clinical management: where are we today?
Alexis Arzimanoglou (FRANCE)
13:30-13:50 Clinical studies: where do we need to be?
Jacqueline French (USA)
13:50-14:10 Clinical decisions: where can we make progress?
Lieven Lagae (BELGIUM)
14:10-14:30 Panel Discussion
All Faculty
Sponsored by
Wednesday, 18 September 2019 MC 2 Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 3
Time is motor neuron in SMA
Chair: Eduardo Tizzano (SPAIN)
13:00-13:05 Welcome and Introduction
Eduardo Tizzano (SPAIN)
13:05-13:25 Nusinersen ▼in infants who initiate treatment in a pre-symptomatic stage of SMA:interim results from the phase 2 NURTURE study (March 2019)
Enrico Bertini (ITALY)
13:25-13:45 Accelerating time to diagnosis in SMA
Ulrike Schara (GERMANY)
13:45-14:05 Prognostic biomarkers in SMA
Basil T. Darras (USA)
14:05-14:25 Emerging challenges of the new SMA phenotypes
Francesco Muntoni (UNITED KINGDOM)
14:25-14:30 Summary and close
Eduardo Tizzano (SPAIN)
Sponsored by
Wednesday, 18 September 2019 MC 3 Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 4
Dravet Syndrome from childhood to adulthood: how to make a successful transition?
Chair: Rima Nabbout (FRANCE)
13:00-13:05 Introduction
Rima Nabbout (FRANCE)
13:05-13:20 Managing Dravet Syndrome through adolescence and adulthood: the parents’
perspective
Isabella Brambilla (SWITZERLAND)
13:20-13:45 Comorbidities associated with Dravet Syndrome, evolution and management
Tiziana Granata (ITALY)
13:45-14:10 How to handle the therapeutical transition?
Stephane Auvin (FRANCE)
14:10-14:25 Questions / Answers
14:25-14:30 Conclusion
Sponsored by
Wednesday, 18 September 2019Mitropoulos Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 5
Adolescence is complicated enough: now add Epilepsy
Chair: Argirios Dinopoulos (GREECE)
13:00-13:05 Welcome – Introduction: improving life-chances in Epilepsy
Argirios Dinopoulos (GREECE)
13:05-13:30 Challenges of living with Epilepsy in adolescence
Georgia Ramantani (SWITZERLAND)
13:30-13:55 Do we under-recognise sleep disturbances in adolescents with Epilepsy?
Adrian Garcia Ron (SPAIN)
13:55-14:20 Managing an increased risk for cognitive dysfunction
Kimford Meador (USA)
14:20-14:30 Q&A: What does this mean for everyday clinical practice?
All Faculty
Sponsored by
Wednesday, 18 September 2019Trianti Hall
18:30-20:00 INDUSTRY SPONSORED SYMPOSIUM 6
Gene Therapy in SCN1A-Related Epilepsies (Dravet Syndrome)
Co-Chairs: Andreas Brunklaus (UNITED KINGDOM), Stephanie Schorge (UNITED KINGDOM)
Faculty: Rubén Hernández (SPAIN), Gabriele Lignani (UNITED KINGDOM), Benit Maru (USA)
18:30-18:45 Overview and background of SCN1A-related epilepsies
18:45-19:00 Introduction to gene therapy
19:00-19:45 Current gene therapy approaches for SCN1A-related epilepsies
19:45-20:00 Q&A session
Sponsored by
Wednesday, 18 September 2019Skalkotas Hall
18:30-20:00 INDUSTRY SPONSORED SYMPOSIUM 7
Rewriting the tale of Sisyphus: the SMA boulder that went up amountain and came down to change a disease
18:30-19:00 Re-writing my story of SMA – How each patient journey is different
Edward Ndopu (SOUTH AFRICA)
19:00-19:20 The SMA patient journey through a clinician’s eyes – What milestones have weachieved
Francesco Muntoni (UNITED KINGDOM)
19:20- 19:40 Natural history and revolution of the disease – Do we know what the future willholdfor SMA and how can we prepare for it
Eugenio Mercuri (ITALY)
19:40- 20:00 Presenter discussion – Q&A
Sponsored by
Wednesday, 18 September 2019MC 3 Hall
18:30-20:00 INDUSTRY SPONSORED SYMPOSIUM 9
Evolution of diagnosis and management in Cerebral Adrenoleukodystrophy
18:30-18:45 Light Dinner Buffet
18:45-18:50 Introductions and Programme Overview
Jorn-Sven Kuhl (GERMANY)
18:50-19:10 Clinical presentation of Cerebral Adrenoleukodystrophy: the importance of earlydiagnosis and treatment
Isabella Moroni (ITALY)
19:10-19:25 Treatment of Cerebral Adrenoleukodystrophy with allogeneic hematopoietic stemcell transplantation
Jorn-Sven Kuhl (GERMANY)
19:25-19:40 Advanced Neuroimaging in the diagnosis and post-treatment monitoring ofCerebral Adrenoleukodystrophy
Florian Eichler (USA)
19:40-19:45 Closing Remarks
Jorn-Sven Kuhl (GERMANY)
19:45-20:00 Q&A
All Faculty
Sponsored by
Thursday, 19 September 2019Trianti Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 11
Duchenne Muscular Dystrophy: from suspicion to treatment
Chair: Eugenio Mercuri (ITALY)
13:00-13:05 Welcome and introduction
Eugenio Mercuri (ITALY)
13:05-13:30 The importance of early diagnosis and timely treatment and management forpatients with DMD
Gunther Bernert (AUSTRIA)
13:30-13:50 Ataluren for the treatment of patients with nmDMD*: latest developments
Eugenio Mercuri (ITALY)
13:50-14:10 Management of nmDMD in patients: clinician’s case study
Talia Dor (ISRAEL)
14:10-14:30 Today’s key learnings and Q&A
Eugenio Mercuri (ITALY)
Sponsored by
Thursday, 19 September 2019Skalkotas Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 12
Severe Paediatric Hypersalivation: its impact on quality of life and the need to manage it effectively
Chair: Coriene Catsman-Berrevoets (NETHERLANDS)
13:00-13:05 Welcome & Introduction
Coriene Catsman-Berrevoets (NETHERLANDS)
13:05-13:30 The Importance of effective assessment and management of Sialorrhea in childrenwith Cerebral Palsy
Lindsey Pennington (UNITED KINGDOM)
13:30-13:55 Why it is time to reconsider our approach to managing Hypersalivation
Jeremy Parr (UNITED KINGDOM)
13:55-14:20 Are you a tablet crusher?
Alastair Patterson (UNITED KINGDOM)
14:20-14:27 Panel Discussion & Interactive Session
Coriene Catsman-Berrevoets (NETHERLANDS)
14:27-14:30 Close
Coriene Catsman-Berrevoets (NETHERLANDS)
Sponsored by
Thursday, 19 September 2019 MC 2 Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 13
The latest & the future: management of LGS and related Epileptic Encephalopathies
13:00-13:05 Introduction
Stephane Auvin (FRANCE)
13:05-13:25 Non-pharmacological treatments for LGS: integration new treatmentrecommendations
Stephane Auvin (FRANCE)
13:25-13:55 Beyond seizures: improving cognitive and behavioral outcomes
Nicola Specchio (ITALY)
13:55-14:15 The current and advances in pharmacological treatments
Sophia Varadkar (UNITED KINGDOM)
14:15-14:30 Closing and Q&A
Sponsored by
Thursday, 19 September 2019 MC 3 Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 14
Gene therapy in Neuromuscular Disorders: the time is now
Chair: Kevin Strauss (USA)
13:00-13:15 Welcome and Introduction
Kevin Strauss (USA)
13:15-13:40 Gene therapy: the past, present and future
Arthur Burghes (USA)
13:40-14:05 Gene therapy and Neuromuscular Disorders: the impact on clinical practice
Francesco Muntoni (UNITED KINGDOM)
14:05-14:25 Panel discussion
All Faculty
14:25-14:30 Symposium close
Kevin Strauss (USA)
Sponsored by
Thursday, 19 September 2019 Mitropoulos Hall
13:00-13:30 INDUSTRY SPONSORED SYMPOSIUM 15
Chronic Drooling in children – Consequences and management – A new era
Chair: Roser Pons (GREECE)
13:00-13:05 Introduction
13:05-13:25 Presentation on Chronic Drooling in children – Consequences and management - Anew era
Rajat Gupta (UNITED KINGDOM)
13:25-13:30 Questions
Helen Shaw (UNITED KINGDOM)
Sponsored by
Friday, 20 September 2019 Skalkotas Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 16
A sense of urgency and the challenging consequences of early-onset rare Epilepsies
Chair: Lieven Lagae (BELGIUM)
Welcome and introduction
Lieven Lagae (BELGIUM)
A sense of urgency in the treatment of rare Epileptic Encephalopathies
Richard Chin (UNITED KINGDOM)
The social and financial burden of living with rare epilepsies
Adam Strzelczyk (GERMANY)
Pronouncing a diagnosis and coping with the aftermath
Tania Korsak (BELGIUM)
Audience Q&A
All
Closing Remarks
Lieven Lagae (BELGIUM)
Sponsored by
Friday, 20 September 2019 MC 2 Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 17
Further tales of the unexpected: early diagnosis in childhood muscular disorders
Chair: Maureen Cleary (UNITED KINGDOM)
13:00-13:10 Introduction
Maureen Cleary (UNITED KINGDOM)
13:10-13:35 Muscle weakness and hyperCKemia: deciphering the diagnosis
Andres Nascimento (SPAIN)
13:35-14:00 Mild motor delay: a common symptom leading to an uncommon diagnosis
Federica Deodato (ITALY)
14:00-14:25 Following the clues to successfully diagnose childhood muscle disorders
Maureen Cleary (UNITED KINGDOM)
14:25-14:30 Closing remarks
Maureen Cleary (UNITED KINGDOM)
Sponsored by
Friday, 20 September 2019 MC 3 Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 18
Targeting respiratory dysfunction in DMD
Chair: Argirios Dinopoulos (GREECE)
13:00-13:10 Welcome and introduction
Argirios Dinopoulos (GREECE)
13:10-13:40 Respiratory function decline as a predictor of clinical outcomes
Oscar H. Mayer (USA)
13:40-14:10 Altering the course of respiratory dysfunction in DMD
Laurent Servais (FRANCE)
14:10-14:15 Summary
Argirios Dinopoulos (GREECE)
14:15-14:30 Q&A and Close
All Faculty
Sponsored by
Friday, 20 September 2019 Banquet Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 19
Development of therapies for Genetic Disorders
Diagnostic journey in Neuromuscular Disorders
Alessandra Ferlini (ITALY)
Genetic therapies and application in Neuromuscular Disorders
Eugenio Mercuri (ITALY)
What can we learn from the Nationwide Gene Therapy Experience?
Linda Lowes (USA)
Sponsored by
Friday, 20 September 2019Mitropoulos Hall
13:00-14:30 INDUSTRY SPONSORED SYMPOSIUM 20
A Window on something rare: understanding AADC deficiency
Chair: Roser Pons (GREECE)
13:00-13:10 Welcome and Introduction
Roser Pons (GREECE)
13:10-13:30 Cerebral palsy mimics and differential diagnosis of AADC deficiency
Roser Pons (GREECE)
13:30-13:50 AADC deficiency: clinical diagnosis based on case studies
Bruria Ben-Zeev (ISRAEL)
13:50–14:10 Current management options and overview of treatments in development
Thomas Opladen (GERMANY)
14:10–14:30 Q&A session
Roser Pons (GREECE)
Sponsored by